Citigroup
IDYA icon

Citigroup’s IDEAYA Biosciences IDYA Stock Holding History

Citigroup’s Portfolio IDYA Stock Details IDYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.99M Buy
+80,100
New +$2.45M ﹤0.01% 2602

Other funds holding IDYA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Citigroup's IDYA Position: Q2 2026 in Review

Citigroup increased its IDEAYA Biosciences (IDYA) stake by 25% in Q2 2026, buying an estimated $676K and bringing the position to 110,970 shares worth $4.14M. The position accounts for ﹤0.01% of the portfolio, ranked #2311.

Citigroup first reported a position in IDYA in Q4 2019 and has held it in 27 quarters since. The position peaked at $9M in Q1 2024. 286 funds tracked by Wall St. Rank hold IDYA as of Q2 2026.

  • Citigroup held 110,970 shares of IDEAYA Biosciences worth $4.14M as of Q2 2026.
  • Citigroup bought 22,090 IDEAYA Biosciences shares in Q2 2026, an estimated $676K.
  • IDEAYA Biosciences made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2311 holding.
  • Citigroup first reported a position in IDEAYA Biosciences in Q4 2019 and has held it in 27 quarters since.
  • Citigroup's IDEAYA Biosciences position peaked at $9M in Q1 2024.
  • 286 funds tracked by Wall St. Rank held IDEAYA Biosciences as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.